News

November 8, 2023
Asahi Kasei Pharma and SBI Biotech announce start of Phase 1 study to evaluate AK1910 as a potential treatment for autoimmune diseases
September 29, 2023
Asahi Kasei Pharma files application for approval to manufacture and sell Cresemba™ Capsule 40 mg as additional formulation in Japan
September 5, 2023
Notice of Issuance of a Provisional Disposition Order on Patent Infringement against a Generic of “Teribone™ Injection”
August 30, 2023
Announcement of listing on the NHI drug price standard and marketing of Empaveli® Subcutaneous Injection 1080 mg in Japan
June 30, 2023
Result of NEDO Smart Cell Project leads to commercial product           Contributing to dyslipidemia testing through supply of material for in vitro diagnostic assays
May 24, 2023
Announcement of listing on the NHI drug price standard and marketing of Doptelet® Tablet 20 mg in Japan
March 15, 2023
Announcement of listing on the NHI drug price standard and marketing of Cresemba™ Capsule 100 mg and Cresemba™ Intravenous Infusion 200 mg in Japan
March 13, 2023
Asahi Kasei Pharma announces the start of a Phase 1 study of next-generation, long-acting GLP-2 analog peptide apraglutide in Japan
December 23, 2022
Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba™ Capsule 100 mg and Cresemba™ Intravenous Infusion 200 mg in Japan
December 9, 2022
Announcement of listing on the NHI drug price standard and marketing of bag product of Reclast® for i.v. infusion 5 mg
September 15, 2022
Asahi Kasei Pharma and Swedish Orphan Biovitrum Japan conclude exclusive distribution agreement for pegcetacoplan, a complement C3 inhibitor for paroxysmal nocturnal hemoglobinuria, and avatrombopag, an agent for improving thrombocytopenia associated with chronic liver disease
August 10, 2022
Approval of additional bag formulation of Reclast® for i.v. infusion 5 mg
August 5, 2022
Asahi Kasei Pharma to solicit proposals for drug discovery research
June 14, 2022
Alchemedicine and Asahi Kasei Pharma Enter into Exclusive License Agreement for Selective Endothelin A Receptor Antagonist
April 28, 2022
Asahi Kasei Pharma filed for provisional injunctions against infringement of patent rights of “TeriboneTM Injection”
March 31, 2022
Asahi Kasei Pharma signs exclusive license agreement with VectivBio to develop and commercialize next-generation GLP-2 analog peptide apraglutide in Japan
March 28, 2022
Start of Japan-US international phase 1 study of ART-123 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN)
October 7, 2021
Asahi Kasei Pharma to solicit proposals for drug discovery research
September 30, 2021
Asahi Kasei Pharma files application for approval to manufacture and sell AK1820 (isavuconazonium sulfate) in Japan
September 30, 2021
Asahi Kasei Pharma obtains exclusive option for AGN1 LOEP Hip Kit
Page Top